TITANIUM PROFESSIONALS

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way for the body to make its own weight - loss drugs, doing away with injections in favor of a one - time treatment.

In a study published in Communications Medicine, researchers from The University of Osaka have revealed that a modified genome editing approach to tackle noncommunicable, multifaceted diseases.

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor - induced type 1 diabetes, a rare but life-threatening side effect of cancer immunotherapy, using an existing class of autoimmune drugs.

The study, published in JCI Insight, identifies a new group of immune cells involved in the development immune checkpoint inhibitor - induced type 1 diabetes and shows that JAK inhibitors,

Among the more than 100 types of human papillomavirus (HPV), at least 14 are considered as 'high-risk' types which can cause (cervical) cancer. After breast cancer, cervical cancer is the most common cancer in Europe among women aged 15 - 44 years [1].

Before HPV vaccination among teenage girls started in Denmark, high-risk HPV was found in all cervical cancers. HPV types 16/18 accounted for around three quarters (74%) of cervical cancers.

An international team led by researchers at The Hospital for Sick Children (SickKids), Princess Margaret Cancer Centre, Dalhousie University, the University of Exeter (UK) and the Medical University of Vienna (Austria) has uncovered a surprising way compartments within cells work together to defend themselves against oxidative stress, a finding that could shift how we understand age-associated conditions such as diabetes and neurodegenerative diseases.

Receiving six or more prescriptions of the drug gabapentin for low back pain is associated with significantly increased risks of developing dementia and mild cognitive impairment (MCI) - 29% and 85%, respectively - finds a large medical records study published online in the journal Regional Anesthesia & Pain Medicine.

What's more, these risks were more than twice as high in those normally considered too young to develop either condition - 18 - 64 year olds - the findings indicate.

A research team led by Prof. LIU Qingsong and Prof. LIU Jing from the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has recently developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant mutant form, offering a promising strategy for treating hematological malignancies.

A new study by University of Bath scientists has highlighted two new potential families of drug molecules that could open the door to new treatments for tuberculosis.

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is the second largest infectious killer globally after COVID-19 and causes 1.3 million deaths annually.

A new study led by researchers at Lund University in Sweden, reveals that melanoma, the deadliest form of skin cancer, can in some cases be driven by mitochondrial processes, which can be effectively targeted using existing drugs. In preclinical laboratory experiments with melanoma cell cultures, researchers successfully eliminated cancer cells by using antibiotics and inhibitors of mitochondrial energy production, highlighting a potential therapeutic breakthrough.

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in delivering multinational randomized clinical trials. The research was the first to comprehensively quantify these barriers for an international platform trial and emphasizes the need for urgent improvements, particularly in preparing for future public health crises.

Researchers working on an incurable blood cancer can now use a new lab model which could make testing potential new treatments and diagnostics easier and quicker, new research has found.

In a paper published in Nature Communications a team of researchers led from the University of Birmingham have studied blood cells from patients with a blood cancer called myelodysplastic syndrome disease (MDS).

Chronic inflammation occurs when the immune system is stuck in attack-mode, sending cell after cell to defend and repair the body for months or even years. Diseases associated with chronic inflammation, like arthritis or cancer or autoimmune disorders, weigh heavily on human health - and experts anticipate their incidence is on the rise. A new study by investigators from Mass General Brigham identified a protein called WSTF that could be targeted to block chronic inflammation.

Gene therapy can improve hearing in children and adults with congenital deafness or severe hearing impairment, a new study involving researchers at Karolinska Institutet reports. Hearing improved in all ten patients, and the treatment was well-tolerated. The study was conducted in collaboration with hospitals and universities in China and is published in the journal Nature Medicine.

A new study published in Nutrients offers new insight into omega-6 and whether it is truly the proinflammatory fatty acid many claim it to be.

There is currently a heightened interest in the health effects of seed oils, many of which are rich in linoleic acid (LA), an essential omega-6 fatty acid.

A new study published in The Lancet has raised urgent concerns about the global health consequences of recent cuts to U.S. foreign aid. The study, coordinated by researchers from the Barcelona Institute for Global Health (ISGlobal), together with the Institute of Collective Health of the Federal University of Bahia (ISC-UFBA), the University of California Los Angeles (UCLA), and the Manhiça Centre for Health Research (CISM), among others, estimates that 91 million deaths were prevented between 2001 and 2021 in low- and middle-income countries (LMICs)

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

Type 2 diabetes (T2D), a condition in which the body can't use insulin to clear sugar from the bloodstream, affects 1 in 10 Americans. It comes with grave health risks, including cardiovascular and kidney disease.

Penn-led researchers have turned a deadly fungus into a potent cancer-fighting compound. After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukemia cells. The result? A promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines.

Lower blood sugar and increased fat burning - without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to produce heat through a process known as thermogenesis, thereby promoting weight loss. In animal tests, the compound prevented fat accumulation in response to a high-fat diet, treated existing obesity, and reversed associated metabolic disorders, including insulin resistance.

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

The results were published in the journal NEJM Evidence.

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML). Standard treatment is often ineffective against AML, a cancer that commonly relapses with poor prognosis, particularly when the disease is fueled by fusion proteins involving NUP98.